Health Care & Life Sciences » Pharmaceuticals | YiChang HEC ChangJiang Pharmaceutical Co. Ltd.

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. | Ownership

Companies that own YiChang HEC ChangJiang Pharmaceutical Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Pinpoint Asset Management Ltd.
10,770,965
4.76%
-501,635
88.75%
03/29/2017
Temasek Holdings Pte Ltd. (Investment Management)
10,760,000
4.76%
-6,500,000
0.11%
06/12/2018
Norges Bank Investment Management
10,642,610
4.71%
-904,202
0.01%
08/16/2018
The Vanguard Group, Inc.
4,738,471
2.1%
5,456
0%
07/31/2018
Oberweis Asset Management, Inc.
3,099,000
1.37%
3,099,000
0.59%
03/31/2018
Baring Asset Management (Asia) Ltd.
3,075,000
1.36%
0
0.46%
10/31/2017
Fidelity Management & Research (Hong Kong) Ltd.
2,908,400
1.29%
0
0.31%
07/31/2018
BlackRock Fund Advisors
2,630,400
1.17%
0
0%
09/06/2018
TIAA-CREF Investment Management LLC
1,010,000
0.45%
0
0%
03/31/2018
HuaAn Fund Management Co., Ltd.
976,400
0.43%
88,000
0.06%
12/31/2017

About YiChang HEC ChangJiang Pharmaceutical Co.

View Profile
Address
Dong YangGuang Park
Dongguan Guangdong 443300
China
Employees -
Website http://www.hec-changjiang.com
Updated 07/08/2019
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. engages in the development, manufacturing and selling of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, cardiovascular diseases and others. Its products include Benzbromarone, Telmisartan, Amlodipine besylate, and Cetirizine hydrochloride. The company was founded on May 11, 2015 and is headquartered in Dongguan, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.